Clinical Analysis of Efficacy Preventing Brain Metastases Treated with Temozolomide and Biotherapy in Malignant Melanoma

Objective To compare the incidence proportions of brain metastases in malignant melanoma patients treated with TMZ plus Cisplatin-based or DTIC-based chemobiotherapy for one year. We further investigated the correlation between MGMT expression and efficacy of TMZ. Methods In 88 cases, 52 patients with malignant melanoma were administered with TMZ and 36 patients were treated with DTIC for one year, then the incidence of brain metastases were calculated and the relationship between the MGMT expression and the efficacy of TMZ were analyzed. Results In TMZ-treated group there were 2 (3.85%) patients with brain metastases. The numbers of brain metastases in the other group were 6 (16.67%). The disease control rate in MGMT negative expression group was 80%, whereas, in MGMT positive expression group it was 40.91%. Conclusion The number of patients with brain metastases was low in TMZ-treated group.The efficacy of TMZ-based chemotherapy is associated with MGMT expression. High efficacy of TMZ treatment was found in patients without MGMT expression.